Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSupportive Therapy, ToxicityProtocol groupComplicationsDiseaseMethotrexate toxicitySubgroupICD10MeSHSequenceChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceGlucarpidaseSupportive substanceGlucarpidaseSupportive substanceGlucarpidaseSupportive substanceGlucarpidaseNo. Substances1Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationTherapy phaseSalvageTherapy intentionsupportiveRisksEmetogenicityHeadacheRash only studiesPublicationAuthorLiebig SOgawa ADiseaseZur Verringerung toxischer verzögerter Ausscheidung von Methotrexat, oder wenn das Risiko einer Methotrexat-Toxizität bestehtZur Verringerung toxischer verzögerter Ausscheidung von Methotrexat bei chronischer Niereninsuffizienz (GFR 40-80 ml/min)OriginDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyNiigata Cancer Center Hospital, Niigata, Japan, CPG2-PII studyProtocols in Revision 2 protocols foundGlucarpidase 2000, Methotrexate toxicity (PID3060 V1.0)Glucarpidase 50, Methotrexate toxicity (PID3039 V1.0)
